OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SNT57

Syntara Ltd

Biotechnology & Medical ResearchVerified

Syntara Ltd has a basic and diluted share count of 1,876,980,111, indicating no immediate dilution pressure from share issuance. However, the liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability and return metrics are not available for Syntara Ltd, as the valuation snapshot does not provide data on return on invested capital (ROIC), gross margins, or operating margins. This lack of data makes it difficult to compare the company's performance against industry benchmarks or cohort medians. The company's revenue concentration and geographic exposure are not disclosed in the available data. Without segment or geographic breakdowns, it is impossible to assess the diversification of Syntara Ltd's revenue streams or its exposure to specific markets. Growth trajectory is not quantifiable due to the absence of historical revenue data and forward-looking guidance. Analysts have provided a mean price target of 0.12 AUD, with a median of 0.12 AUD, but these estimates do not reflect a clear consensus on the company's future performance. Risk factors include the unassessed liquidity risk and the lack of detailed financial disclosures. The dilution risk is currently low, but the absence of balance-sheet inputs limits the ability to evaluate the company's financial health comprehensively. Recent events and filings do not provide additional insights into Syntara Ltd's operations or strategic direction. The lack of detailed disclosures and financial data suggests a need for further due diligence before making investment decisions.

30-day price · SNT-0.01 (-16.1%)
Low$0.03High$0.03Close$0.03As of13 May, 00:00 UTC
Profile
CompanySyntara Ltd
TickerSNT.AX
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Syntara Ltd is a biotechnology and medical research company operating in the healthcare sector, primarily engaged in pharmaceuticals and medical research.

Classification. Syntara Ltd is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.

Syntara Ltd has a basic and diluted share count of 1,876,980,111, indicating no immediate dilution pressure from share issuance. However, the liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability and return metrics are not available for Syntara Ltd, as the valuation snapshot does not provide data on return on invested capital (ROIC), gross margins, or operating margins. This lack of data makes it difficult to compare the company's performance against industry benchmarks or cohort medians. The company's revenue concentration and geographic exposure are not disclosed in the available data. Without segment or geographic breakdowns, it is impossible to assess the diversification of Syntara Ltd's revenue streams or its exposure to specific markets. Growth trajectory is not quantifiable due to the absence of historical revenue data and forward-looking guidance. Analysts have provided a mean price target of 0.12 AUD, with a median of 0.12 AUD, but these estimates do not reflect a clear consensus on the company's future performance. Risk factors include the unassessed liquidity risk and the lack of detailed financial disclosures. The dilution risk is currently low, but the absence of balance-sheet inputs limits the ability to evaluate the company's financial health comprehensively. Recent events and filings do not provide additional insights into Syntara Ltd's operations or strategic direction. The lack of detailed disclosures and financial data suggests a need for further due diligence before making investment decisions.
Key takeaways
  • Syntara Ltd has a basic and diluted share count of 1,876,980,111, indicating no immediate dilution pressure.
  • The company's liquidity risk remains unassessed due to the absence of balance-sheet inputs.
  • Profitability and return metrics are not available, making it difficult to compare against industry benchmarks.
  • Analysts have provided a mean price target of 0.12 AUD, but there is no clear consensus on the company's future performance.
  • The company's revenue concentration and geographic exposure are not disclosed, limiting the ability to assess diversification.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyAUD
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$22.8M-$4.4M-$3.0M-$465.0k
FY-3$14.8M-$15.4M-$1.9M$995.0k
FY-2$5.9M-$14.3M-$11.4M-$11.7M
FY-1$5.4M-$14.1M-$15.1M-$13.4M
FY0$7.5M-$12.4M-$7.9M-$12.0M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$33.6M$2.8M$9.3M
FY-3$25.2M$10.8M$2.5M
FY-2$24.0M$9.6M$6.0M
FY-1$10.4M$4.7M
FY0$21.4M$16.0M
PeriodOCFCapExFCFSBC
FY-4$3.1M-$647.0k-$465.0k
FY-3-$16.1M-$307.0k$995.0k
FY-2-$7.3M-$138.0k-$11.7M
FY-1-$14.5M-$7.0k-$13.4M
FY0-$11.1M$0.00-$12.0M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricSNTActivity
Op margin2.4% medp25 -91.8% · p75 12.5%
Net margin1.2% medp25 -98.4% · p75 10.4%
Gross margin45.6% medp25 29.8% · p75 66.7%
CapEx / revenue-5.2% medp25 -15.8% · p75 -1.7%
Debt / equity9.3% medp25 0.1% · p75 43.8%
Observations
IR observations
Mean price target0.12 AUD
Median price target0.12 AUD
High price target0.19 AUD
Low price target0.06 AUD
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count2.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-0.60 AUD
Last actual EPS-0.01 AUD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 13:12 UTC#0eeddd04
Market quoteclose AUD 0.03 · shares 1.63B diluted
no public URL
2026-05-05 03:32 UTC#d1af5260
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 12:23 UTCJob: 2ee39f19